Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$98.3M
119M shares
52-week range
$0.73 – $1.51
10% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
www.oncolyticsbiotech.comNo one on the platform currently holds ONCY.
No tracked institution reports a position in ONCY as of their last filing.
No one on the platform has traded ONCY yet.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1M | +3.2% | $-0.35 | $-0.39–$-0.32 | — | 4 |
| 2027 | $594629 | -49.9% | $-0.29 | $-0.35–$-0.23 | — | 4 |
| 2028 | $13M | +2031.7% | $-0.22 | $-0.36–$-0.02 | — | 5 |
| 2029 | $73M | +474.9% | $0.02 | $0.02–$0.02 | 46.2× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-12 | $-0.05 | $-0.08 | -48.7% |
| 2026-05-14 | $-0.05 | $-0.08 | -60.0% |
| 2026-03-30 | $-0.06 | $-0.08 | -33.3% |
| 2025-11-12 | $-0.12 | $-0.10 | +16.7% |
| 2025-08-08 | $-0.11 | $-0.05 | +54.5% |
| 2025-05-14 | $-0.09 | $-0.06 | +33.3% |
| 2025-03-07 | $-0.08 | $-0.07 | +12.5% |
| 2024-11-12 | $-0.08 |
| $-0.09 |
| -12.5% |
| $594M |
| — |
| MGNXMacroGenics, Inc. | $4.08 | +1.49% | $259M | — |
| SRZNSurrozen, Inc. | $23.73 | -1.90% | $177M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$ONCY BP and institutional biotech funds do not care if Oncy was incorporated decades ago. If the upcoming REO 033 Part A and Goblet c5 readouts prove that pela turns "cold" GI tumors "hot" in a randomized setting, the stock will rerate based purely on future peak sales potential and probability of success, not historical trading patterns.
View on StockTwits ↗$ONCY 127.5 outstanding shares. 161.6 fully diluted. The green CEO who started his tenure with promises of ending ATM's & improving shareholder value has lost my confidence, not that I ever afforded him much anyway. He can't find money/partnerships so how is a R/S avoided?
View on StockTwits ↗$ONCY That was the core of the game for the last 28 years. No BPs interest. No tutes interest. Just a few pumpers left. The rest are dissapointed longs holding to hopeless hopes. Nobody wants this old dog full of flees. The new puppy is AI discovery drug programs. GLTA.
View on StockTwits ↗$ONCY positive thoughts everyone, we need something in the next 2 weeks to get this going again!
View on StockTwits ↗$ONCY my bet is that the investors get fuked over here... massive dilution and reverse split likely ahead... I have no confidence in Jared... his move to Nevada was strategic.
View on StockTwits ↗$ONCY https://finance.yahoo.com/community/post/f5616109-1197-4045-a650-a5c6074bf7ce/
View on StockTwits ↗$ONCY https://finance.yahoo.com/community/post/1c4a8dc1-9788-4c49-9f44-59bb2e0d85e6/
View on StockTwits ↗$ONCY It’s all very nice, but they’ve run out of money, so it’s either a minimal buyout or heavy dilution. I don’t think there are any other options.
View on StockTwits ↗$ONCY very peaceful on the board without someone posting 25-45 billion times each day. Now just waiting for the news.
View on StockTwits ↗$ONCY the position oncy is in—<1$, cash runway measured in quarters not years, moderate short interest, and 100m+ OS—is not unique at all in the biotech space. Getting above 1$ and sustaining it based on a major de risking event like a type D meeting to align on a streamlined path to registration is also not unique.
View on StockTwits ↗$ONCY I find it unusual that there was no PR this morning about the Q2 release. They would never miss that PR????????? The D meeting must have be today!!
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.